Therapeutic peptides showed an exponentially growth in interest over the course of the last years, in particular those related to the treatment of diabetes and weight control, such as the Glucagon Like Peptide 1 (GLP-1) agonist. Their molecular complexity is however challenging and requires the development of tailored chromatographic analytical tools to efficiently assess their related substance profile. In the present paper, we performed the comparison of two orthogonal approaches related to Electrostatic Repulsion-Reversed Phase (ERRP) chromatography, namely the static ERRP and dynamic ERRP, with the aim to assess their capabilities in terms of resolution. Both the approaches were applied to the GLP-1 derivative Liraglutide as case study, focusing the attention on classical impurities associated with peptide products, such as epimers and endo/eso impurities.
Manetto, S., Mazzoccanti, G., Bassan, M., Macis, M., Cabri, W., Ciogli, A., et al. (2025). Comparing the performance of electrostatic repulsion-reversed phase chromatography approaches in the resolution of complex peptide mixture: Liraglutide as case study. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 211, 1-8 [10.1016/j.ejps.2025.107120].
Comparing the performance of electrostatic repulsion-reversed phase chromatography approaches in the resolution of complex peptide mixture: Liraglutide as case study
Cabri W.;
2025
Abstract
Therapeutic peptides showed an exponentially growth in interest over the course of the last years, in particular those related to the treatment of diabetes and weight control, such as the Glucagon Like Peptide 1 (GLP-1) agonist. Their molecular complexity is however challenging and requires the development of tailored chromatographic analytical tools to efficiently assess their related substance profile. In the present paper, we performed the comparison of two orthogonal approaches related to Electrostatic Repulsion-Reversed Phase (ERRP) chromatography, namely the static ERRP and dynamic ERRP, with the aim to assess their capabilities in terms of resolution. Both the approaches were applied to the GLP-1 derivative Liraglutide as case study, focusing the attention on classical impurities associated with peptide products, such as epimers and endo/eso impurities.| File | Dimensione | Formato | |
|---|---|---|---|
|
2025 European Journal of Pharmaceutical Sciences 2025, 211, 107120.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale / Version Of Record
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
2.23 MB
Formato
Adobe PDF
|
2.23 MB | Adobe PDF | Visualizza/Apri |
|
2025 European Journal of Pharmaceutical Sciences 2025, 211, 107120 SI.docx
accesso aperto
Tipo:
File Supplementare
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
229.66 kB
Formato
Microsoft Word XML
|
229.66 kB | Microsoft Word XML | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


